Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 (Vaxneuvance) vs Prevenar 13 in Healthy Infants (PNEU-PED-EU-2)
NCT04016714Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2019
- Primary completion
- Oct 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 5
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Aug 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04016714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016714.